CN1371688A - Medicinal application of VC phosphate ester magnesium - Google Patents
Medicinal application of VC phosphate ester magnesium Download PDFInfo
- Publication number
- CN1371688A CN1371688A CN 01106185 CN01106185A CN1371688A CN 1371688 A CN1371688 A CN 1371688A CN 01106185 CN01106185 CN 01106185 CN 01106185 A CN01106185 A CN 01106185A CN 1371688 A CN1371688 A CN 1371688A
- Authority
- CN
- China
- Prior art keywords
- magnesium
- magnesium phosphorate
- phosphorate
- medicine
- weight percentage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention relates to a new medicinal application of food additive VC-phosphate ester magnesium. In said invention is used as active component, and combined with one or several kinds of excipient, the conventional process is used to make them into tablet, granules, powder or syrup and capsule preparation as caccagogue. It has no any toxic side effect, and possesses health-care action.
Description
The present invention relates to the new application of Vc-magnesium phosphorate, particularly relate to the application in the preparation laxative.
Vc-magnesium phosphorate, English name are Ascorbyl phosphate magnesium, are called for short AP-Mg.
The molecular formula of AP-Mg: C
6H
6O
9PMg
1.55H
2O
Molecular weight is: 379.61
Structural formula is:
The AP-Mg purposes is wider, usually as food additive, does not still have the report of using as laxative.
1, present, the cathartic kind of treatment constipation is a lot, is broadly divided into three classes by its mechanism of action: (1) irritant laxative: all belong to this type of as commercially available phenolphthalein tablet, hypocatharsis sheet, Triacephentinum, bisatin, hemp intestine-moistening sheet (ball) etc.; (2) saline cathartic; As magnesium sulfate, sodium sulfate etc.; (3) emollient laxative; As glycone, glycerin etc.But these cathartics equal alleviate constipation patient's in clinical practice misery, but all there are some side effect to some extent, life-time service also can cause the custom dependency, even cause losing of calcium and vitamin, cause avitaminosis, therefore, constipation patient especially in, gerontal patient and pregnant, puerpera constipation person want these cathartics of careful selection.(draw from～" consultant of family " Beijing Publishing House, in February, 1980 front page P335-336.)
The objective of the invention is to the new pharmaceutical usage that utilizes AP-Mg to have, make caccagogue.What both can overcome that existing cathartic exists easily causes patient's vitamin deficiency, even easily causes deficiency such as spastic colon constipation, can take into account the effect that replenishes necessary vitamin C of human body and magnesium ion into human body again.
The object of the present invention is achieved like this:
With AP-Mg as active ingredient, combine with one or more excipient, make tablet, granule, powder or syrup by technological operations such as tablet, granule, powder, syrups, also can directly active ingredient be incapsulated and make capsule, be used for laxative action, wherein the consumption of AP-Mg accounts for the 0.6-100% of accumulated dose.
Can be decomposed into Vc and magnesium ion after the AP-Mg absorption of human body.Vc is the vitamin of human body requirement maximum, can strengthen immune function of human body, prevents and treats the generation of vitamin C deficiency and multiple disease.Magnesium ion also has plurality of health care functions, is the 4th cation of needed by human, with the functional activity of many enzymes important relationship is arranged, but catalysis or activate body 300 plurality of enzymes system, so magnesium ion is the key element of all energy metabolisms in the body.In the zoopery of adopting AP-Mg to carry out, find that it has the promotion gastrointestinal motility, increase Absorption, and then softening Excreta, reach cathartic, prevent the effect of constipation gastrointestinal tract moisture content.AP-Mg to the influence of white mice gastrointestinal motility, to the influence of white mice intestinal absorption moisture and discharge function result thereof see Table 1 respectively, table 2, table 3.
1, AP-Mg is to the influence of mice gastrointestinal motility
(1) method: choose 50 of the Kunming kind white mice of healthy weight 18-23g, female 12, male 38, be divided into 5 groups, 10 every group, blank group is given ordinary water, and the positive drug group gives 80 respectively, 2835Mg.kg
-1Magnesium sulfate, the administration group gives 80 respectively, 2835Mg.kg
-1AP-Mg, all irritate stomach by the 0.6ml/20g volume, all irritate stomach after 15 minutes with 10% charcoal end, after 15 minutes white mice being taken off neck puts to death, taking out gastrointestinal tract, has been point measurement small intestinal total length and charcoal end displacement with pylorus, calculates the percentage rate that charcoal end displacement accounts for the small intestinal total length.Intestinal motility has zero difference between t method of inspection calculating group with contrasting between group.
(2) conclusion; The results are shown in Table 1, AP-Mg2835Mg.kg
-1The dosage group has facilitation to intestinal motility, and its advance distance and propelling rate and blank group comparing difference remarkable (p＜0.01) are better than the positive drug group, and this test shows that AP-Mg has facilitation to gastrointestinal motility under doses.
2, AP-Mg is to the effect of white mice intestinal absorption moisture content
(1) method: get 60 of healthy mices, body weight 18-23 gram is divided into 4 groups, and 15 every group, blank group is given ordinary water, and the positive drug group gives 5000Mg.kg
-1MgSO
4, the administration group gives 2500 respectively, 5000Mg.kg
-1AP-Mg, all by the 0.6ml/20g volume irritate stomach give with, white mice was taken off neck in 1 hour behind the medicine and puts to death, the full intestinal weight of weighing respectively, between organizing with the t check relatively.
(2) conclusion: the results are shown in Table 2, AP-Mg has the effect that increases the intestinal moisture absorption, 2500Mg.kg
-1The dosage group increases the effect and the MgSO of intestinal moisture content
45000 Mg.kg
-1Dosage is suitable.
3, the discharge function of AP-Mg
(1) method: 72 of healthy mices are divided equally 6 groups, and 12 every group, blank group is given ordinary water, all the other each groups are given 50% sucralfate, all give by 1ml//day, and hunger is spent the night two days later continuously, with above-mentioned half amount filling stomach once blank group was given ordinary water after half an hour in the 3rd day, and the positive drug group is given 5000Mg.kg
-1MgSO
4, model group gives that 50% sucralfate, administration group give 2500,5000 respectively, 7500Mg.kg
-1AP-Mg all irritates stomach by the 0.6mL/20g volume.Began to write down respectively in 1 hour behind the medicine and respectively organize mice accumulative total defecation grain number in 30,60,120,180,360 minutes each time periods, with between group relatively the t method of inspection calculate group difference.
(2) conclusion: the results are shown in Table 3, positive drug and AP-Mg5000Mg.kg
-1Dosage group and model group comparing difference are remarkable, (between P＜0.05-0.001), AP-Mg2500Mg.kg
-1Discharge function is promptly arranged, AP-Mg5000Mg.kg
-1With MgSO
45000Mg.kg
-1Discharge function approaching, show AP-Mg5000Mg.kg
-1Dosage have and MgSO
4Identical discharge function.
Invention advantage: be not difficult to find out that from above-mentioned zoopery result the fast and strong positive drug magnesium sulfate effect of AP-Mg discharge function and discharge function is suitable.Use AP-Mg to have as cathartic that a medicine is used, the characteristics of safety non-toxic more in addition, both can avoid the side effect of existing cathartic, can be human body again increases necessary nutrition, has also widened the range of application of AP-Mg simultaneously.Its major advantage is; (1) the AP-Mg free of toxic effects is safe in utilization.(2) AP-Mg do not have smell, tasteless, the stimulating gastrointestinal road is not easy to be accepted.(3) the AP-Mg discharge function relaxes.(4) the AP-Mg stable in properties is difficult for oxidation, is not afraid of alkali, not influenced by the ferrum plasma, easily stores.(5) high temperature resistant, be not destroyed in 25 minutes 218 ℃ of bakings.(6) low price, easy to manufacture, do not produce environmental pollution.
Carry out on the zooperal basis at AP-Mg, use with the animal experiment dose,equivalent and take for numerical example custom constipation patient, each 200Mg (AP-Mg) (capsule) was administered three times on the 1st, had also obtained satisfied cathartic effect.
Excipient generally includes starch, lactose, sucrose, essence etc. among the present invention.Further specify the preparation method of preparation of the present invention by the following examples.
Embodiment 1
Patrol following prescription and make AP-Mg tablet (used content is weight percentage)
AP-Mg 50％
Lactose 25%
Starch 24%
Stearic acid 1%
(1) with AP-Mg, lactose pulverize separately, cross 100 mesh sieves, direct mistake 100 mesh sieves of starch are standby;
(2) get appropriate amount of starch and be mixed with 10% gelatinized corn starch, make adhesive fully;
(3) with AP-Mg, lactose and surplus starch mixing, add the soft ability of adhesive system, cross 16 mesh sieve system granules;
(4) wet granular is placed in about 50 ℃ of drying baker about 3 hours of forced air drying;
(5) dried granule adds magnesium stearate, mix homogeneously behind 16 mesh sieve granulate;
(6) with the flat stamping of diameter 90mm, promptly.
Embodiment 2
Make AP-Mg capsule (used content is weight percentage) by following prescription
AP-Mg?48％
Starch 52%
(1) AP-Mg, starch are passed through 100 mesh sieves respectively, carry out pretreatment;
(2) the abundant mix homogeneously of AP-Mg, starch that will be treated;
(3) medicated powder with mixing is filled into No. 2 capsulae vacuuses promptly.
Get and pulverize, and cross the AP-Mg100g of 100 mesh sieves, be filled into respectively in No. 2 capsulae vacuuses, promptly get pure AP-Mg capsule.
Embodiment 3
Make AP-Mg powder (used content is weight percentage) by following prescription
AP-Mg 10％
Icing Sugar 90%
With AP-Mg and Icing Sugar pulverize separately, cross 100 mesh sieves, the method that employing equivalent is progressively increased is with the two mix homogeneously, and subpackage is promptly.
Embodiment 4
Make AP-Mg granule (used content is weight percentage) by following prescription
AP-Mg 6％
Cane sugar powder 94%
After AP-Mg pulverized, cross 100 mesh sieves, with an amount of Icing Sugar mix homogeneously, other gets sucrose and is configured to 50% syrup in right amount, joins in the material of above-mentioned mixing, and the system soft material is granulated by 12 mesh sieves, oven dry, and after 12 mesh sieve granulate, pack gets final product.
Embodiment 5
Make AP-Mg dry syrup (used content is weight percentage) by following prescription
AP-Mg 5％
Cane sugar powder 93%
Citric acid 1.745%
Fructus Citri tangerinae flavor essence 0.125%
Orange flavor essence 0.125%
(1), cross 100 mesh sieves with AP-Mg, sucrose, citric acid pulverize separately:
(2) get AP-Mg, citric acid and an amount of Icing Sugar mixing;
(3) get in addition that an amount of sucrose is made into 50% syrup and pigment incorporated wherein make adhesive fully;
(4) adhesive that step (3) is made joins in the material of step (2) mixing, and the system soft material is crossed 12 mesh sieves and granulated, drying, behind the granulate promptly.
Claims (7)
1, the application of Vc-magnesium phosphorate in medicine is characterized in that adopting the Vc-magnesium phosphorate as active component, makes the laxative of treatment constipation disease.
2, the application of Vc-magnesium phosphorate according to claim 1 in medicine, it is characterized in that adopting the Vc-magnesium phosphorate to combine with one or more excipient as active ingredient, make tablet, granule, syrup by technological operations such as tablet, granule, syrups, also active ingredient can be incapsulated and make capsule, the active component consumption is the 0.6-100% of whole amount of formulation by weight percentage.
3, the application of Vc-magnesium phosphorate according to claim 1 and 2 in medicine is characterized in that Vc-magnesium phosphorate active ingredient consumption is 50% by weight percentage, and dosage form is a tablet.
4, the application of Vc-magnesium phosphorate according to claim 1 and 2 in medicine is characterized in that Vc-magnesium phosphorate active component consumption is 48% or 100% by weight percentage, and dosage form is a wafer.
5, the application of Vc-magnesium phosphorate according to claim 1 and 2 in medicine is characterized in that Vc-magnesium phosphorate active component content is 10% by weight percentage, and dosage form is a powder.
6, Vc-magnesium phosphorate according to claim 1 and 2 is characterized in that Vc-magnesium phosphorate active component content is 6% by weight percentage, and dosage form is a granule.
7, the application of Vc-magnesium phosphorate according to claim 1 and 2 in medicine is characterized in that Vc-magnesium phosphorate active component content is 5% by weight percentage, and dosage form is a dry syrup.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011061855A CN1143678C (en) | 2001-02-23 | 2001-02-23 | Medicinal application of VC phosphate ester magnesium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011061855A CN1143678C (en) | 2001-02-23 | 2001-02-23 | Medicinal application of VC phosphate ester magnesium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1371688A true CN1371688A (en) | 2002-10-02 |
| CN1143678C CN1143678C (en) | 2004-03-31 |
Family
ID=4655225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011061855A Expired - Fee Related CN1143678C (en) | 2001-02-23 | 2001-02-23 | Medicinal application of VC phosphate ester magnesium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1143678C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8999313B2 (en) | 2012-09-11 | 2015-04-07 | Norgine Bv | Compositions |
| US9592252B2 (en) | 2011-03-11 | 2017-03-14 | Norgine Bv | Colonoscopy—preparation |
-
2001
- 2001-02-23 CN CNB011061855A patent/CN1143678C/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9592252B2 (en) | 2011-03-11 | 2017-03-14 | Norgine Bv | Colonoscopy—preparation |
| US10646512B2 (en) | 2011-03-11 | 2020-05-12 | Norgine Bv | Colonoscopy - preparation |
| US10780112B2 (en) | 2011-03-11 | 2020-09-22 | Norgine Bv | Colonoscopy-preparation |
| US10792306B2 (en) | 2011-03-11 | 2020-10-06 | Norgine Bv | Colonoscopy—preparation |
| US11529368B2 (en) | 2011-03-11 | 2022-12-20 | Norgine Bv | Colonoscopy—preparation |
| US8999313B2 (en) | 2012-09-11 | 2015-04-07 | Norgine Bv | Compositions |
| US9326969B2 (en) | 2012-09-11 | 2016-05-03 | Norgine Bv | Compositions |
| US9707297B2 (en) | 2012-09-11 | 2017-07-18 | Norgine Bv | Compositions |
| US10016504B2 (en) | 2012-09-11 | 2018-07-10 | Norgine Bv | Compositions |
| US10918723B2 (en) | 2012-09-11 | 2021-02-16 | Norgine Bv | Colon cleansing compositions and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1143678C (en) | 2004-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102488753B (en) | Fishing Chinese medicinal composition with antibacterial and antibiotic functions and preparation method thereof | |
| CN102949710A (en) | Pharmaceutical composition or healthcare product for increasing bone mineral density and preparation method of pharmaceutical composition or healthcare product | |
| CN102512531B (en) | Chinese veterinary medicinal composition for preventing and treating pullorum and preparation method of same | |
| AU2020101274A4 (en) | Sunflower disc extract and medical use thereof in the treatment of constipation | |
| CN103393713A (en) | Hyaluronic acid and application of salt thereof in preparing medicines for treating constipation | |
| CN1201786C (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN106822097B (en) | Orlistat-containing pharmaceutical composition for losing weight | |
| CN105125621A (en) | Oral composition with immunity enhancement function | |
| CN1143678C (en) | Medicinal application of VC phosphate ester magnesium | |
| CN106924270B (en) | Orlistat-containing pharmaceutical composition with weight-losing function | |
| CN1233260C (en) | Chinese medicine fodder additives for increasing milk and fitting cow and preparing method | |
| CN102018801B (en) | Novel digestion promoting tablets and preparation method thereof | |
| CN1232184C (en) | Immunity-regulating and fatigue-resisting health food | |
| CN1864740A (en) | A Chinese medicinal composition for clearing heat and expelling toxin and preparation method thereof | |
| CN106063788B (en) | Application of phillyrin, phillyrin derivatives, and phillyrin-phillygenin composition in preparation of drugs for relieving or/and treating emesis | |
| CN109601880B (en) | Health food for increasing bone mineral density | |
| CN1686211A (en) | Medicine for treating acute and chronic pharyogolaryngitis, recurring oral cavity sore and its preparation method | |
| CN1130212C (en) | Medicine for treating abdominal node and its preparing process | |
| CN101972412B (en) | Composition of tall gastrodia tuber and lecithin, and preparation method thereof | |
| CN1389265A (en) | Composite Chinese medicine with health care function | |
| CN105770054A (en) | Pharmaceutical composition for preventing and treating chicken coccocidiosis, additive and feed | |
| CN115299546B (en) | Chinese medicinal extract effervescent tablet and preparation method thereof | |
| CN1803148A (en) | Stomatocace-treating medicine and its preparation method | |
| CN106491664A (en) | A kind of Chinese medicine composition for treating pig virus diarrhoea | |
| CN1259928C (en) | Quickly dissolving amaranth seed powder for lower sugar content (in blood or urine) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: NORTHEAST PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: NORTHEAST PHARMACEUTICAL HEAD FACTORY |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 110026, No. 37, North Street, heavy industry, Tiexi District, Liaoning, Shenyang Patentee after: Northeast Pharmaceutical Group Co., Ltd. Address before: 110026, No. 37, North Street, heavy industry, Tiexi District, Liaoning, Shenyang Patentee before: Dongbei Pharmaceutical Factory |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040331 Termination date: 20160223 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |